MX2021004329A - 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. - Google Patents
2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos.Info
- Publication number
- MX2021004329A MX2021004329A MX2021004329A MX2021004329A MX2021004329A MX 2021004329 A MX2021004329 A MX 2021004329A MX 2021004329 A MX2021004329 A MX 2021004329A MX 2021004329 A MX2021004329 A MX 2021004329A MX 2021004329 A MX2021004329 A MX 2021004329A
- Authority
- MX
- Mexico
- Prior art keywords
- synucleinopathies
- tauopathies
- suppressing
- treating
- nonylcyclohexa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
- C07C50/04—Benzoquinones, i.e. C6H4O2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747080P | 2018-10-17 | 2018-10-17 | |
| US201862771570P | 2018-11-26 | 2018-11-26 | |
| PCT/US2019/056836 WO2020081879A2 (en) | 2018-10-17 | 2019-10-17 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004329A true MX2021004329A (es) | 2021-06-08 |
Family
ID=68503208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004329A MX2021004329A (es) | 2018-10-17 | 2019-10-17 | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. |
| MX2024005493A MX2024005493A (es) | 2018-10-17 | 2021-04-15 | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005493A MX2024005493A (es) | 2018-10-17 | 2021-04-15 | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11174212B2 (https=) |
| EP (2) | EP4257190A3 (https=) |
| JP (2) | JP7586815B2 (https=) |
| KR (1) | KR20210076956A (https=) |
| CN (2) | CN113365616A (https=) |
| AU (1) | AU2019362010A1 (https=) |
| BR (1) | BR112021007153A2 (https=) |
| CA (2) | CA3116866A1 (https=) |
| CL (1) | CL2021000948A1 (https=) |
| CO (1) | CO2021006356A2 (https=) |
| DK (1) | DK3866772T3 (https=) |
| EC (1) | ECSP21034596A (https=) |
| ES (1) | ES2968957T3 (https=) |
| FI (1) | FI3866772T3 (https=) |
| HU (1) | HUE066196T2 (https=) |
| IL (1) | IL282375A (https=) |
| MX (2) | MX2021004329A (https=) |
| MY (1) | MY210324A (https=) |
| PE (1) | PE20211600A1 (https=) |
| PH (1) | PH12021550859A1 (https=) |
| PL (1) | PL3866772T3 (https=) |
| SG (1) | SG11202103887VA (https=) |
| TN (1) | TN2021000075A1 (https=) |
| WO (1) | WO2020081879A2 (https=) |
| ZA (1) | ZA202102619B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| TN2021000075A1 (en) | 2018-10-17 | 2023-01-05 | Ptc Therapeutics Inc | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
| WO2021077034A1 (en) * | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
| MX2024000445A (es) * | 2021-07-08 | 2024-04-05 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona. |
| WO2024050725A1 (en) | 2022-09-07 | 2024-03-14 | Ptc Therapeutics, Inc. | Methods of producing 2, 3, 5, 6-alkyl-1, 4-benzoquinones |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08768B2 (ja) | 1989-08-24 | 1996-01-10 | 武田薬品工業株式会社 | 神経成長因子分泌誘導剤 |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| CA2252519A1 (en) | 1996-07-11 | 1998-01-22 | Keisuke Hirai | Use of idebenone and analogues against beta amyloid induced cytotoxicity |
| CN1302287A (zh) | 1998-05-22 | 2001-07-04 | 盐野义生物研究公司 | 生物还原性细胞毒试剂 |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| EP1378753B1 (en) | 2002-07-01 | 2006-05-31 | Santhera Pharmaceuticals (Schweiz) GmbH | A screening method and compounds for treating Friedreich Ataxia |
| AU2003287250B9 (en) | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| ES2619303T3 (es) | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| SI1933821T1 (sl) * | 2005-09-15 | 2020-11-30 | Ptc Therapeutics, Inc. | Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev |
| WO2007095631A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | New drug delivery system for crossing the blood brain barrier |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2008086025A2 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| EP2242506A4 (en) | 2008-01-07 | 2011-12-28 | Janssen Biotech Inc | METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS |
| US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US20090291092A1 (en) | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| MX363223B (es) * | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| US20120136048A1 (en) | 2009-04-28 | 2012-05-31 | Miller Guy M | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
| EA201101576A1 (ru) | 2009-04-28 | 2012-04-30 | Эдисон Фармасьютикалз, Инк. | Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний |
| EP2445519A4 (en) | 2009-06-25 | 2012-12-26 | Ampere Life Sciences Inc | TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS USING TOCOTRIENOLS OR TOCOTRIENOLS ENRICHED EXTRACTS |
| NO2470168T3 (https=) | 2009-08-26 | 2018-06-30 | ||
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| BR112012022634A2 (pt) | 2010-03-09 | 2019-09-24 | Edison Pharmaceuticals Inc | síntese de derivados de alto-tocoferolquinona e métodos de utilização dos mesmos |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| CA2795726A1 (en) | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| JP5902673B2 (ja) | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Ptc Therapeutics, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| CN105142603B (zh) | 2013-03-08 | 2018-10-19 | 荷兰联合利华有限公司 | 用于皮肤病用途的间苯二酚化合物 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| EP3004071A1 (en) | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| DK3233786T3 (da) | 2014-12-16 | 2022-05-09 | Ptc Therapeutics Inc | Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid |
| JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
| WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| TN2021000075A1 (en) | 2018-10-17 | 2023-01-05 | Ptc Therapeutics Inc | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
| US20230002324A1 (en) | 2019-06-13 | 2023-01-05 | Ptc Therapeutics, Inc. | Naphthoquinone derivatives for treatment of oxidative stress disorders |
| WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
-
2019
- 2019-10-17 TN TNP/2021/000075A patent/TN2021000075A1/en unknown
- 2019-10-17 CA CA3116866A patent/CA3116866A1/en active Pending
- 2019-10-17 ES ES19801443T patent/ES2968957T3/es active Active
- 2019-10-17 MX MX2021004329A patent/MX2021004329A/es unknown
- 2019-10-17 EP EP23193936.4A patent/EP4257190A3/en not_active Withdrawn
- 2019-10-17 SG SG11202103887VA patent/SG11202103887VA/en unknown
- 2019-10-17 AU AU2019362010A patent/AU2019362010A1/en not_active Abandoned
- 2019-10-17 EP EP19801443.3A patent/EP3866772B1/en active Active
- 2019-10-17 BR BR112021007153-9A patent/BR112021007153A2/pt unknown
- 2019-10-17 WO PCT/US2019/056836 patent/WO2020081879A2/en not_active Ceased
- 2019-10-17 CA CA3255913A patent/CA3255913A1/en active Pending
- 2019-10-17 KR KR1020217014520A patent/KR20210076956A/ko active Pending
- 2019-10-17 PE PE2021000524A patent/PE20211600A1/es unknown
- 2019-10-17 CN CN201980083477.1A patent/CN113365616A/zh active Pending
- 2019-10-17 HU HUE19801443A patent/HUE066196T2/hu unknown
- 2019-10-17 CN CN202411357523.1A patent/CN119185268A/zh active Pending
- 2019-10-17 JP JP2021521219A patent/JP7586815B2/ja active Active
- 2019-10-17 DK DK19801443.3T patent/DK3866772T3/da active
- 2019-10-17 PL PL19801443.3T patent/PL3866772T3/pl unknown
- 2019-10-17 MY MYPI2021002086A patent/MY210324A/en unknown
- 2019-10-17 FI FIEP19801443.3T patent/FI3866772T3/fi active
-
2021
- 2021-03-30 US US17/218,042 patent/US11174212B2/en active Active
- 2021-04-15 MX MX2024005493A patent/MX2024005493A/es unknown
- 2021-04-16 CL CL2021000948A patent/CL2021000948A1/es unknown
- 2021-04-16 PH PH12021550859A patent/PH12021550859A1/en unknown
- 2021-04-18 IL IL282375A patent/IL282375A/en unknown
- 2021-04-20 ZA ZA2021/02619A patent/ZA202102619B/en unknown
- 2021-05-14 CO CONC2021/0006356A patent/CO2021006356A2/es unknown
- 2021-05-14 EC ECSENADI202134596A patent/ECSP21034596A/es unknown
- 2021-11-10 US US17/523,880 patent/US11667596B2/en active Active
-
2022
- 2022-01-25 US US17/584,362 patent/US11746077B2/en active Active
-
2023
- 2023-07-05 US US18/347,068 patent/US20230339835A1/en active Pending
-
2024
- 2024-08-16 JP JP2024136955A patent/JP2024161510A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004329A (es) | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. | |
| MX2024001205A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso. | |
| CO2019007906A2 (es) | Inhibidores de poli-adp ribosa polimerasa (parp) | |
| DOP2018000031A (es) | DERIVADOS DE 1,1,1-TRIFLUORO-3-HIDROXIPROPAN-2-IL CARBAMATO y DERIVADOS DE 1,1,1-TRIFLUORO-4-HIDROXIBUTAN-2-IL CARBAMATO COMO INHIBIDORES DE MAGL | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| MX2019001036A (es) | Tratamiento y prevencion de los trastornos del sueño. | |
| MX2017006832A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. | |
| WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2016015436A (es) | Compuestos para tratar el cancer cerebral. | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| MX2023013508A (es) | Inhibicion de la proteina de union a creb (cbp). | |
| EP3347010A4 (en) | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| CL2023000100A1 (es) | 2,3,5-trimetil-6-nonilclohexa-2,5-diena-1,4-diona para suprimir y tratar alfa-sinucleinopatías, tauopatías y otros trastornos | |
| BR112015028884A2 (pt) | tratamento ou prevenção de depressão utilizando mentol e/ou icilina | |
| BR112015007095A2 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados |